Evonik's Methionine-Fueled Quarter: Beyond the One-Trick Pony?
Evonik Industries' Q2 2026 earnings call was dominated by two intertwined narratives: a surprisingly strong quarter that the company insists is far more than a trick pony, and an aggressive restructuring plan that aims to reshape the company's cost base for the long term. The results themselves were stellar — adjusted EBITDA up 24% year-over-year to EUR 630 million, the best quarterly figure in four years — but the strategic commentary suggests this is not just a cyclical blip.
A Strong Quarter, but the Narrative Is Methionine
CEO Christian Kullmann was visibly proud of the results, but quickly pivoted to the broader story: “we have more potential, even more potential than others.” — Christian Kullmann, Chief Executive Officer (CEO) · 2026-08-04 Much of that potential, he argued, lies in methionine, where Evonik's global footprint gives it a unique pricing and cost advantage. When an analyst called Evonik a "one trick pony" on methionine, Kullmann pushed back with characteristic flair, highlighting the company's methionine capacity across the U.S., Europe, and Asia, and its backward integration in the U.S. plant. He went further, predicting a "shakeout" among weaker competitors in 2027 that would strengthen Evonik's market position.
The market clearly agrees. Methionine prices have stayed elevated due to supply chain disruptions and competitor outages, and the company expects Q3 to be the best quarter yet for the business. CFO Michael Rauch confirmed that both volumes and prices contributed 7 percentage points each to growth, and that the strength is broad-based — crosslinkers, polymers, and C4 also delivered. As he put it: “Our strong operating results converted nicely into cash,” — Michael Rauch, Chief Financial Officer (CFO) · 2026-08-04 with free cash flow benefiting from lower bonus payments and reduced working capital outflows.
Right-Sizing for the Long Term
The earnings beat is being used to fund an even deeper restructuring. In the call, Kullmann announced an extension of the Evonik Tailor program, aiming to reduce another 3,200 positions between 2027 and 2029, on top of the 2,800 already planned. CFO Michael Rauch detailed that the split would shift from 80/20 admin-to-operations to a more balanced 60/40, reflecting a holistic approach across the entire business. When pressed on how investors should think about the net savings, Rauch was candid: “many of the assumptions that were done no longer held true” — Michael Rauch, Chief Financial Officer (CFO) · 2026-08-04 due to inflation, so the net impact has been less pronounced. This is a sobering admission, but the company remains committed to cost discipline as a "hygiene factor."
Capital allocation is also under scrutiny. The new dividend policy, which takes effect in 2027, gives the company more flexibility, but CFO Rauch was clear that deleveraging and organic investment take precedence over buybacks for now: “we will make sure that we utilize the cash as we always do in order, first, to fuel our organic business; second, to make sure that we also pay a reasonable dividend.” — Michael Rauch, Chief Financial Officer (CFO) · 2026-08-04 This echoes CFO Claus Rettig's earlier stance in February, when he said, “CapEx is number one... like I said, we have topics which we get fast returns.” — Claus Rettig, CFO · 2026-02-06
The EU Tailwind and the Shakeout Bet
Beyond company-specific actions, Evonik is banking on regulatory tailwinds. Kullmann enthusiastically welcomed the European Commission's proposals to overhaul the emissions trading system, calling it a step towards a level playing field for European industry. He expects negotiations to intensify after the summer and hinted at further lobbying. This is a recurring theme — in previous calls he described the ETS as a potential "game changer" — and now the company sees concrete progress. The European Union angle is intertwined with Evonik's strategic positioning: cheaper energy and a more competitive regulatory framework would particularly benefit its European assets, including the Oxeno business that remains in the divestment queue.
We are now summer 2026, and I hope that I will be able to enjoy my summer vacation in a couple of days. And in the meanwhile, I will start to think about what could be prudent how to manage our attractive located methionine capacities in 2027.
That quote captures the determined-but-measured tone of the call. Evonik is not resting on its laurels; it is using the current windfall to fund structural improvements and prepare for a future where methionine prices may normalize. The company's own keyword trajectory shows a sharp spike in interest around "methionine prices" and "Evonik tailor" in the latest quarter, reflecting how central these themes have become to the investor conversation.
Ultimately, this is a story of a company that has found a temporary tailwind but is determined not to waste it. Whether the cost cuts and EU reforms will offset the eventual methionine downcycle remains the key question — but for now, Evonik is making the most of its moment.